Research programme: psychiatric disorder therapeutics - Camino Pharma

Drug Profile

Research programme: psychiatric disorder therapeutics - Camino Pharma

Alternative Names: SBP 0069330

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Camino Pharma
  • Developer Camino Pharma; Sanford Burnham Prebys Medical Discovery Institute; University of California, San Diego
  • Class Antidepressants; Drug withdrawal therapies; Small molecules
  • Mechanism of Action Metabotropic glutamate receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cocaine abuse; Smoking withdrawal
  • Research Depressive disorders

Most Recent Events

  • 03 Oct 2017 Early research in Depressive disorders (Treatment-resistant) in USA (PO) (Camino Pharma pipeline, October 2017)
  • 27 Sep 2017 Preclinical trials in Cocaine abuse in USA (PO)
  • 27 Sep 2017 Preclinical trials in Smoking withdrawal in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top